

PRESS RELEASE – FOR IMMEDIATE DISTRIBUTION

IntegraGen and Advanced Biological Laboratories sign global licensing agreement for the commercialization of miRpredX test

ÉVRY, France and LUXEMBOURG City, Luxembourg (March 5, 2019) - IntegraGen, a company specializing in the transformation of data from biological samples into genomic information and diagnostic tools for oncology, and Advanced Biological Laboratories (ABL), a leading integrated diagnostics and medical IT company, announced today the signing of a non-exclusive global licensing agreement enabling ABL to distribute miRpredX™, IntegraGen's proprietary IVD CE marked diagnostic test that enables clinicians to identify metastatic colorectal cancer patients who have a higher likelihood of response to anti-EGFR therapy.

“IntegraGen has compiled a vast amount of clinical data demonstrating the clinical benefit of testing miR-31-3p expression in RAS wild-type metastatic colorectal cancer patients that shows that these patients will have increased benefit from treatment with anti-EGFR therapy. We believe the miRpredX test will enable ABL to provide its worldwide network of clinicians and distributors a unique option to improve patient care,” stated Chalom Sayada Ph.D., Founder and CEO of ABL SA. “We look forward to making the miRpredX test available to our global network immediately and expect a strong demand for this test from leading oncologists.”

“This global partnership with ABL is another significant step for IntegraGen Diagnostics since it will enable physicians worldwide to utilize miR-31-3p testing to assist with personalizing their approach to the treatment of patients with metastatic colorectal cancer,” added Bernard Courtieu, IntegraGen's CEO. “Following our agreement with GoPath Laboratories in 2018 for North America, our agreement with ABL now makes our miR-31-3p expression test available in all major geographies across the globe. We look forward to partnering with ABL to make this test widely available to clinicians.”

About Metastatic Colorectal Cancer

Colorectal cancer is third most common cancer in men and second most common in women with over 1.3 million new cases annually on a worldwide basis. This includes over 345,000 new cases in Europe and 135,000 new cases in the United States on an annual basis.¹ An estimated 25% of patients with colorectal cancer will present with metastatic disease at the time of diagnostic with up to an additional 50% of patients developing mCRC following initial diagnosis.² An estimated 694,000 deaths from CRC occur worldwide every year, accounting for 8.5% of all cancer deaths and making it the fourth most common cause of death from cancer.¹ Approximately 50% of patients with metastatic colorectal cancer, representing 347,000 patients worldwide, have RAS wild-type tumors.³

1. World Health Organization – International Agency for Research on Cancer, 2017
2. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D for the ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2014; 25 Suppl 3:iii1-9.
3. Peeters M, et al. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials. *Eur J Cancer.* 2015; 51:1704-13.

About Advanced Biological Laboratories (ABL SA)

Advanced Biological Laboratories (ABL), S.A., is a Diagnostic and Medical Software company founded in 2000 as a spin-off from CRP-Santé Luxembourg. ABL's products offer to infectious disease clinicians, virology and microbiology laboratories optimal and efficient solutions (assays and software systems related to HIV, Tuberculosis, HCV, HBV, HPV, CMV, HPV, Flu...) for sequencing (DeepChek®) clinical genotyping, viral load (UltraGene™) and drug resistance analysis, including powerful fully integrated databases and analysis systems that combine standard and high-throughput Next Generation Sequencing data. ABL took control of TherapyEdge, Inc. in 2004 and in 2013 the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL as well as a personalized medicine electronic medical record system (EMR) in infectious disease from GlaxoSmithKline in 2016. In July 2018, acquired CDL Pharma to develop CRO related services and assays manufacturing capacity. ABL has a comprehensive suite of healthcare management products, including Nadis®, TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, UltraGene®, VisibleChek®, HepatiC® and the DPM used for data and patient management, monitoring and personalized. reporting applications. In 2012, some of ABL's products also received CE-marking for IVD use. ABL's products like ViroScore® Suite and DeepChek® are for research use only in the United States, and the data processing module is an FDA registered class I medical device. These are currently available for Research Use Only.

About IntegraGen

IntegraGen is a company specializing in deciphering the human genome and producing relevant and easily interpretable data for academic and private laboratories. IntegraGen's oncology efforts provide researchers and clinicians with sophisticated tools for analysis and therapeutic individualization of treatment approaches allowing them to tailor therapy to the genetic profiles of patients. As of December 31, 2018, IntegraGen had 44 employees and generated revenue of €6.9 million in 2018. Based in Evry Genopole, IntegraGen also has an U.S. office in Cambridge, Massachusetts. IntegraGen is listed on Euronext Growth (ISIN: FR0010908723 - Ticker: ALINT - PEA-SME).

For more information, visit www.integragen.com



CONTACTS

IntegraGen

Bernard COURTIEU
President and CEO

Laurence RIOT LAMOTTE
Chief Financial Officer
contact@integragen.com
Tel.: +33 (0)1 60 91 09 00

NewCap

Investor and Media Relations
Louis-Victor DELOUVRIER
integragen@newcap.eu
Tel.: +33 (0)1 44 71 98 53

Advanced Biological Laboratories

Dr. Chalom Sayada
CEO
contact@ablsa.com
Tel.: +352 26 38 96 76